The panel reviewed Dr. Strasberg’s case on metastatic pancreatic NET management, highlighting CapTem's high response rates, individualized use of PRRT, and balancing treatment efficacy with long-term toxicity risks.

Dr. Parikh reviewed rare gallbladder small cell carcinoma, highlighting chemoradiation, uncertain immunotherapy benefit, emerging DLL3-targeted therapies, and the need for molecular-guided treatment.

Dr. Anthony presented long-term metastatic NET management, highlighting durable benefit from multimodal therapy. The panel favored earlier PRRT use while weighing liver-directed therapy risks and quality of life.

Dr. Chauhan reviewed immunotherapy in neuroendocrine tumors, noting limited benefit in well-differentiated disease but promising responses in poorly differentiated tumors and emerging DLL3-targeted therapies.

The panel reviewed DLL3-targeted therapies, radiopharmaceutical advances, and theranostics, highlighting promising alpha-PRT trials, beta-emitter safety, and ongoing research into combination and CAR T strategies.